Tvardi Therapeutics(DE:69C)
€1.10-0.07 (-5.98%)
DE:69C
Tvardi Therapeutics earnings date
€1.10
At close:-0.07 (-5.98%)
Tvardi Therapeutics (69C) Q2 2023 Earnings Report
1 Followers
DE:69C Q2 2023 EPS Results
- Actual EPS
- -EUR 18.87
- Consensus EPS
- -EUR 17.52
- Beat/Miss
- Missed by -EUR 1.36
- One Year Ago EPS
- -EUR 2.60
DE:69C Q2 2023 Revenue Results
- Actual Revenue
- EUR 6.27M
- Expected Revenue
- EUR 5.87M
- Beat/Miss
- Beat by +EUR 395.92K
- YoY Revenue Growth
- -69.86%
Earnings Announcement Details
- Quarter
- Q2 2023
- Date
- 08/07/2023
- Time
- After Close
- Conference Call
- Monday, August 7, 2023
DE:69C Upcoming Earnings
Tvardi Therapeutics's next earnings date is estimated for April 6, 2027, based on past reporting schedules.
Q2 2023 Earnings Call Audio
DE:69C Q2 2023 Earnings Call
0:00 / 0:00
Q2 2023 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2023 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:69C Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 06, 2027 | 2026 (Q4) | ―- | -0.66 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | -0.52-0.48 | -0.53 | 9.32% (+0.05) | |
| Aug 14, 2026 | 2026 (Q2) | -0.64-0.62 | -0.9 | 31.00% (+0.28) | |
| May 08, 2026 | 2026 (Q1) | ―- | -2.91 | ― | |
| Mar 31, 2026 | 2025 (Q4) | -0.67-0.66 | -2.91 | 77.33% (+2.25) | |
| Nov 13, 2025 | 2025 (Q3) | -0.90-0.53 | -7.4 | 92.80% (+6.87) | |
| Aug 14, 2025 | 2025 (Q2) | -0.62-0.90 | -11.9 | 92.41% (+11.00) | |
| May 13, 2025 | 2025 (Q1) | -0.53-2.91 | -18.22 | 84.03% (+15.31) | |
| Feb 26, 2025 | 2024 (Q4) | ―-1.52 | -6.4 | 76.27% (+4.88) | |
| Nov 04, 2024 | 2024 (Q3) | -0.22-0.21 | -0.47 | 56.15% (+0.26) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
